Significance of therapeutic dose monitoring of busulfan and targeted dose adjustment in transplantation-Reference-Cited by-同舟云学术

Significance of therapeutic dose monitoring of busulfan and targeted dose adjustment in transplantation

Published:2023 Issue:1 Volume:12 Page:12-17
ISSN:2436-455X
Container-title:Japanese Journal of Transplantation and Cellular Therapy
language:en
Short-container-title:Japanese Journal of Transplantation and Cellular Therapy

Author:

Kato Motohiro¹

Affiliation:

1. Department of Pediatrics, the University of Tokyo

Publisher

The Japan Society for Hematopoietic Stem Cell Transplantation

Link

https://www.jstage.jst.go.jp/article/tct/12/1/12_22-009/_pdf

Reference18 articles.

1. 1. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer chemotherapy and pharmacology 1989; 25: 55-61.

2. 2. Seydoux C, Battegay R, Halter J, et al. Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2022; 57: 903-910.

3. 3. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.

4. 4. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167-173.

5. 5. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925-930.